CIBC Asset Management
RPRX icon

CIBC Asset Management’s Royalty Pharma RPRX Stock Holding History

CIBC Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.91M Buy
34,087
+3,863
+13% +$201K ﹤0.01% 656
2026
Q1 		$1.45M Buy
30,224
+654
+2% +$28.6K ﹤0.01% 672
2025
Q4 		$1.14M Buy
29,570
+43
+0.1% +$1.64K ﹤0.01% 692
2025
Q3 		$1.04M Buy
29,527
+121
+0.4% +$4.38K ﹤0.01% 670
2025
Q2 		$1.06M Buy
29,406
+2,334
+9% +$77.3K ﹤0.01% 662
2025
Q1 		$843K Buy
27,072
+953
+4% +$30.2K ﹤0.01% 688
2024
Q4 		$666K Buy
26,119
+1,028
+4% +$27.3K ﹤0.01% 710
2024
Q3 		$710K Buy
25,091
+905
+4% +$25.1K ﹤0.01% 698
2024
Q2 		$638K Buy
24,186
+12,537
+108% +$348K ﹤0.01% 704
2024
Q1 		$354K Sell
11,649
-210
-2% -$6.19K ﹤0.01% 790
2023
Q4 		$333K Buy
+11,859
New +$326K ﹤0.01% 789
2023
Q1 		– Sell
-14,157
Closed -$559K – 1124
2022
Q4 		$559K Sell
14,157
-11,709
-45% -$489K ﹤0.01% 716
2022
Q3 		$1.04M Buy
25,866
+46
+0.2% +$1.97K ﹤0.01% 663
2022
Q2 		$1.08M Sell
25,820
-931
-3% -$38.2K ﹤0.01% 645
2022
Q1 		$1.04M Buy
26,751
+92
+0.3% +$3.61K ﹤0.01% 687
2021
Q4 		$1.06M Buy
26,659
+2,343
+10% +$91K ﹤0.01% 679
2021
Q3 		$879K Buy
24,316
+1,070
+5% +$41.6K ﹤0.01% 710
2021
Q2 		$953K Buy
23,246
+5
+0% +$213 ﹤0.01% 691
2021
Q1 		$1.01M Buy
+23,241
New +$1.1M ﹤0.01% 661

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIBC Asset Management's RPRX Position: Q2 2026 in Review

CIBC Asset Management increased its Royalty Pharma (RPRX) stake by 13% in Q2 2026, buying an estimated $201K and bringing the position to 34,087 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #656.

CIBC Asset Management first reported a position in RPRX in Q1 2021 and has held it in 19 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • CIBC Asset Management held 34,087 shares of Royalty Pharma worth $1.91M as of Q2 2026.
  • CIBC Asset Management bought 3,863 Royalty Pharma shares in Q2 2026, an estimated $201K.
  • Royalty Pharma made up ﹤0.01% of CIBC Asset Management's portfolio in Q2 2026, its #656 holding.
  • CIBC Asset Management first reported a position in Royalty Pharma in Q1 2021 and has held it in 19 quarters since.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.